axitinib
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
NICE U-turn on Pfizer drug Inlyta
March 5, 2014Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta
NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Pfizer’s cancer drug meets end points in head-to-head study
May 20, 2011Research and Development, Sales and Marketing Pfizer, axitinib, rcc
Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
Pfizer lung cancer drug gets ‘rolling’ fast-track status in US
January 13, 2011Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer
Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …
Pfizer’s axitinib impresses in head-to-head trial with Nexavar
November 22, 2010Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma
Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
Latest content
Five Facts about cardiovascular disease
